AR023366A1 - Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra - Google Patents

Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra

Info

Publication number
AR023366A1
AR023366A1 ARP990106863A ARP990106863A AR023366A1 AR 023366 A1 AR023366 A1 AR 023366A1 AR P990106863 A ARP990106863 A AR P990106863A AR P990106863 A ARP990106863 A AR P990106863A AR 023366 A1 AR023366 A1 AR 023366A1
Authority
AR
Argentina
Prior art keywords
treatment
manufacture
inhibition
matrix
paratratation
Prior art date
Application number
ARP990106863A
Other languages
English (en)
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of AR023366A1 publication Critical patent/AR023366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Uso de benzolactamas N-carboximetil sustituídas de formula 1 donde A es -OH y -NRR y los sustituyentes son como se definen en la memoria descriptiva parala fabricacion de un medicamento para inhibicion de las metaloproteinasas de la matriz (MMPs) enun paciente necesitado de ello administrable en una cantidadinhibidora efectiva de metaloproteinasa de matriz. Tales inhibidores también se usan para la fabricacion de un medicamento para tratamiento de un estado deenfermedad neoplásica, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y para enfisema inducido por fumar. Nuevasbenzolactamas N-carboximetil sustituídas de formula (1a): donde Aa es -NRR y los sustituyentes son como se definen en la memoriadescriptiva. Composicionfarmacéutica que incluye los compuestos de formula (1a)
ARP990106863A 1998-12-31 1999-12-30 Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra AR023366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22454998A 1998-12-31 1998-12-31

Publications (1)

Publication Number Publication Date
AR023366A1 true AR023366A1 (es) 2002-09-04

Family

ID=22841168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106863A AR023366A1 (es) 1998-12-31 1999-12-30 Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra

Country Status (5)

Country Link
EP (1) EP1150957A1 (es)
AR (1) AR023366A1 (es)
AU (1) AU1836900A (es)
CA (1) CA2358955A1 (es)
WO (1) WO2000040564A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2797416T (lt) 2011-12-28 2017-10-25 Global Blood Therapeutics, Inc. Pakeistieji benzaldehido junginiai ir jų panaudojimo būdai, didinant audinių aprūpinimą deguonimi
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX2015011445A (es) 2013-03-15 2016-04-20 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina.
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
BR112015032160B1 (pt) 2014-02-07 2021-11-30 Global Blood Therapeutics, Inc Ansolvato cristalino de composto, composição e composição farmacêutica
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491143A (en) * 1990-10-18 1996-02-13 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
DK0625987T3 (da) * 1992-02-14 1999-01-11 Merrell Pharma Inc Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
DK0750631T3 (da) * 1994-02-14 2000-10-23 Merrell Pharma Inc Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[c]azepin-3-ondisulfidderivater som enkephalinase- og ACE-inhibitorer
ES2131806T3 (es) * 1994-02-14 1999-08-01 Merrell Pharma Inc Nuevos derivados de disulfuro de mercaptoacetilamida utiles como inhibidores de encefalinasa y ace.
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
WO2000040564A1 (en) 2000-07-13
CA2358955A1 (en) 2000-07-13
AU1836900A (en) 2000-07-24
EP1150957A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
AR023366A1 (es) Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra
DK0766665T3 (da) Metalloproteinaseinhibitorer
GEP20043238B (en) Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO308130B1 (no) Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinasehemmere samt anvendelse av samme for fremstilling av medikament
FI971412A0 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
MX9603520A (es) Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso.
AR015349A1 (es) Nuevas modificaciones cristalinas del 2-amino-4-(4-fluorbencilamino)-1-etoxicarbonil-aminobenceno y procedimiento para prepararlos, utilizacion de losmismas y medicamento que las contienen
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
IS6194A (is) Serínprótínasar úr fiski og notkun þeirra í lyf og snyrtivörur
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
EE04938B1 (et) Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
BR0109483A (pt) Pró-drogas de derivados de imidazopiridina
BR0110184A (pt) Derivado de piridina-1-óxido, e processo para a sua transformação em compostos farmaceuticamente eficazes
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
AR032553A1 (es) Derivados de alfa-amino-n-hidroxi-acetamida.
AR011061A1 (es) Compuestos inhibidores de cetona t-terminal de metaloproteinasas de matriz y de la secrecion fent alfa, uso del mismo para la manufactura de un medicamenty una composicion que los contiene
DK374584A (da) Analgetikum
AR023079A1 (es) Pirrolidinas 3-sustituidas utiles como inhibidores de las metaloproteinasas de la matriz, composicion farmaceutica y usos para la fabricacion decomposiciones farmaceuticas para tratamiento de enfermedades.
UY27429A1 (es) Medicamento para el tratamiento terapéutico o preventivo de la tuberculosis que comprende un derivado de eritromicina
PT1165596E (pt) Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem
AR025498A1 (es) Una nueva asociacion farmaceutica que presenta un efecto analgesico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal